Ischemic Stroke Due to Heparin-induced Thrombocytopenia during Severe COVID-19 Infection

Intern Med. 2022 Sep 15;61(18):2797-2801. doi: 10.2169/internalmedicine.9531-22. Epub 2022 Jul 5.

Abstract

A 53-year-old woman with severe coronavirus disease 2019 (COVID-19) pneumonia was admitted and treated with intravenous unfractionated heparin for thromboprophylaxis under general anesthesia with mechanical ventilation. She developed right hemiparesis after hospitalization due to a large hemorrhagic infarction. Her platelet count decreased from 243,000/μL at administration to 121,000/μL. Anti-platelet factor 4-heparin antibody testing was positive according to a latex immunoturbidimetric assay. She was therefore diagnosed with heparin-induced thrombocytopenia. We immediately stopped the heparin and started argatroban; the platelet count recovered, and thrombosis did not relapse. Physicians should consider heparin-induced thrombocytopenia as a cause of ischemic stroke in patients with COVID-19 infection.

Keywords: COVID-19; heparin-induced thrombocytopenia; ischemic stroke.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / adverse effects
  • COVID-19* / complications
  • Female
  • Heparin / adverse effects
  • Humans
  • Ischemic Stroke* / etiology
  • Middle Aged
  • Thrombocytopenia* / chemically induced
  • Thrombocytopenia* / drug therapy
  • Venous Thromboembolism* / drug therapy

Substances

  • Anticoagulants
  • Heparin